Science Explorer Interactive view Map
Company · Chicago · ??

Novalex Therapeutics (United States)

Research works
1
▼ 79% vs 2013–17
Citations
58
40.0 per fractional work
Top-10% rate
17.2%
record average 16.5%
Open access
83%
world 28%

Not ranked overall: Novalex Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which research topics does Novalex Therapeutics (United States) publish most on?

By volume: Antimicrobial Resistance in Staphylococcus, Antibiotic Resistance in Bacteria, Antimicrobial agents and applications and Biochemical and Structural Characterization.

  1. 1 Antimicrobial Resistance in Staphylococcus Infectious Diseases 0 works
  2. 2 Antibiotic Resistance in Bacteria Molecular Medicine 0 works
  3. 3 Antimicrobial agents and applications Organic Chemistry 0 works
  4. 4 Biochemical and Structural Characterization Molecular Biology 0 works
  5. 5 Malaria Research and Control Public Health, Environmental and Occupational Health 0 works
  6. 6 Molecular spectroscopy and chirality Spectroscopy 0 works
  7. 7 Virology and Viral Diseases Epidemiology 0 works
  8. 8 Mosquito-borne diseases and control Public Health, Environmental and Occupational Health 0 works
  9. 9 Antimicrobial Peptides and Activities Microbiology 0 works
  10. 10 Protein Structure and Dynamics Molecular Biology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available82.8%not open17.2%

World: 28% of research is openly available.

How has Novalex Therapeutics (United States)'s research output changed?

Output in 2018–2022 was 79% lower than in 2013–2017.

Other research institutions in Chicago

All research institutions in Chicago

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.